MARKET

BPTH

BPTH

Bio-Path Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.58
-0.31
-5.26%
After Hours: 5.30 -0.28 -5.02% 19:45 04/16 EDT
OPEN
5.90
PREV CLOSE
5.89
HIGH
5.93
LOW
5.51
VOLUME
299.89K
TURNOVER
--
52 WEEK HIGH
24.34
52 WEEK LOW
3.120
MARKET CAP
38.77M
P/E (TTM)
-1.9591
1D
5D
1M
3M
1Y
5Y
8-K: BIO-PATH HOLDINGS INC
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 3d ago
H.C. Wainwright Thinks Bio-Path Holdings’ Stock is Going to Recover
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Bio-Path Holdings (BPTH), with a price target of $12.00. The company's
SmarterAnalyst · 4d ago
DJ Bio-Path Says Preclinical Data Support BP1002 Combination Therapy in Leukemia
Dow Jones · 5d ago
Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today
Benzinga · 5d ago
Antisense Oligonucleotides Market 2020 Dynamics, Comprehensive Analysis, Business Growth, Prospects and Opportunities by 2027
Apr 10, 2021 (Market Insight Reports) -- Global Antisense Oligonucleotides MarketAntisense oligonucleotides are short, single-strand RNA or DNA molecules....
Market Insight Reports · 04/10 06:56
Chronic Myelogenous Leukemia Treatment Market Size to Record Significant Growth Through 2025
Apr 09, 2021 (Market Insight Reports) -- Growth forecast report " Chronic Myelogenous Leukemia Treatment Market size by Product Type (Disease Specific...
Market Insight Reports · 04/09 10:26
Bio-Path Holdings (BPTH) Receives a Rating Update from a Top Analyst
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bio-Path Holdings (BPTH) today and set a price target of $12.00. The company's shares closed
SmarterAnalyst · 04/06 11:55
Thinking about buying stock in Castor Maritime, Zomedica, AMC Entertainment, Palantir Technologies, or Bio-Path Holdings?
NEW YORK, April 5, 2021 /PRNewswire via COMTEX/ -- NEW YORK, April 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTRM, ZOM,...
PR Newswire - PRF · 04/05 14:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BPTH. Analyze the recent business situations of Bio-Path Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BPTH stock price target is 12.50 with a high estimate of 13.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 36
Institutional Holdings: 867.15K
% Owned: 12.48%
Shares Outstanding: 6.95M
TypeInstitutionsShares
Increased
5
77.25K
New
4
63.09K
Decreased
2
1.94K
Sold Out
1
1
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Chief Financial Officer/Treasurer/Director
Peter Nielsen
Secretary/Director/IR Contact Officer
Douglas Morris
Independent Director
Paul Aubert
Independent Director
Heath Cleaver
Independent Director
Martina Molsbergen
No Data
About BPTH
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company's drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately three antisense drug candidates in development to treat a total of over five different cancer disease indications.

Webull offers kinds of Bio-Path Holdings Inc stock information, including NASDAQ:BPTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPTH stock methods without spending real money on the virtual paper trading platform.